Ozempic
Product Images NDC 0169-4136

Product Visual Gallery

This gallery contains 100 technical images submitted to the FDA as part of the official labeling for Ozempic (NDC 0169-4136). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novo Nordisk Pharmaceutical Industries, Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Export 00

Ozempic 1.34 mg/mL injectable solution carton from Novo Nordisk Pharmaceutical Industries, LP. The packaging shows the product name prominently, with the strength 1.34 mg/mL indicated. The label includes relevant usage and manufacturer information with a purple and white color scheme.*

FDA Label Image

Structural Formula (Image 01)

Chemical structure of the active ingredient in Ozempic, showing its peptide chain and attached molecular groups in a detailed diagram.*

FDA Label Image

Figure 1 (Image 02)

A line graph depicting plasma glucose levels (mg/dL) over 24 hours following a breakfast meal. It compares four groups: OZEMPIC 0.68 mg, OZEMPIC 1 mg, placebo baseline, and placebo 1 mg, showing changes in glucose concentration measured at multiple time points after eating.*

FDA Label Image

Figure 2 (Image 03)

A line graph depicting insulin secretion rate (pmol/kg/min) on the y-axis versus plasma glucose (mg/dL) on the x-axis, comparing different treatment groups including subjects treated with Ozempic (semaglutide) at baseline and at 1 mg end of treatment, placebo groups, and healthy subjects. The graph shows trends of insulin secretion changes across plasma glucose levels.*

FDA Label Image

Figure 3 (Image 04)

A chart showing relative exposure (average concentration) ratios and 90% confidence intervals for semaglutide by intrinsic factors including sex, age groups, race, ethnicity, body weight categories, and renal impairment levels. The graph compares exposure to a reference subject profile, indicating variations across these intrinsic factors.*

FDA Label Image

Figure 4 (Image 05)

A data table presenting the relative exposure ratios and 90% confidence intervals for various co-administered medications with associated dosing recommendations. The table includes drugs such as Metformin, S-warfarin, R-warfarin, Digoxin, Atorvastatin, Ethinylestradiol, and Levonorgestrel, with a recommendation of no dose adjustment for all listed medications.*

FDA Label Image

Figure 5 (Image 06)

A line graph comparing HbA1c percentages over weeks post-randomization for Ozempic 0.5 mg, Ozempic 1 mg, and Sitagliptin. The x-axis represents weeks from 0 to 56, and the y-axis shows HbA1c percentages from about 6.0 to 8.5%. The graph includes patient counts for each treatment over time, illustrating changes in HbA1c levels with error bars at week 56.*

FDA Label Image

Warning 1 (Image 07)

Ozempic 1.34 mg/mL injection solution carton from Novo Nordisk Pharmaceutical Industries, LP. The packaging shows the brand name Ozempic prominently with the active ingredient strength stated as 1.34 mg/mL. The product is presented as a multi-dose pen for subcutaneous injection, with details on the quantity inside the box, which includes pens containing the medication. The label includes visual brand elements consistent with Novo Nordisk's design.*

FDA Label Image

Device 1 (Image 08)

An instructional diagram of the Ozempic pen and NovoFine Plus needle showing parts and features labeled, including the pen cap, pen window, dose counter, dose pointer, dose selector, dose button, and expiration date location. The needle assembly is also broken down into outer needle cap, inner needle cap, needle, and paper tab. Additional dose guidance symbols are shown, such as the flow check symbol and dashed line used for dose guidance.*

FDA Label Image

A (Image 09)

An instructional illustration showing hands adjusting or assembling parts on a medical device, likely an injection pen, with a focus on twisting or turning a component to prepare the device for use.*

FDA Label Image

B (Image 10)

Instructional illustration showing a hand holding an Ozempic injection pen with the cap being removed, demonstrating the first step in preparing the injection device for use.*

FDA Label Image

Flow_symbol (Image 100)

The image shows the packaging label for Ozempic, a product by Novo Nordisk Pharmaceutical Industries, LP. The label indicates available strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The packaging is primarily white with purple and orange accents, including the Novo Nordisk logo.*

FDA Label Image

Symbol (Image 101)

Ozempic injection vial label showing dose strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The label includes the proprietary name Ozempic and indicates it is manufactured by Novo Nordisk Pharmaceutical Industries, LP. The design displays dosing and product identification details on a blue and white background.*

FDA Label Image

4 mg/3 mL Carton (8-9514-31-301-1)

Packaging label for Ozempic (semaglutide) injection prefilled pen, 2.68 mg/mL strength, by Novo Nordisk Pharmaceutical Industries, LP. The label indicates single patient use, subcutaneous injection, and dosage increments of 2 mg. The design shows the pen device image, dosing instructions, and company logo on a white and gold background.*

FDA Label Image

Image 103

Packaging label for Ozempic (semaglutide) injection 1 mg in a 4 mg/mL (1.34 mg/mL) prefilled pen. The label indicates single patient use only and delivery in 1 mg increments. It is a subcutaneous injection pen from Novo Nordisk Pharmaceutical Industries, LP. The label also shows the pen image and includes usage instructions with a schedule for weekly injections.*

FDA Label Image

Image 104

An instructional diagram showing components of the Ozempic pen and NovoFine Plus needle. It illustrates the pen cap, pen window, expiration date label location, dose counter, dose pointer, dose selector, and dose button on the Ozempic pen. Separately, it shows parts of the needle including outer needle cap, inner needle cap, needle, and paper tab, with flow check symbols and a dashed line for dose guidance.*

FDA Label Image

Image 105

An instructional illustration showing hands holding a pen-like device with an arrow indicating the removal of a cap or cover. This image is likely part of a usage or preparation guide for a medical injection device.*

FDA Label Image

Image 106

An instructional illustration showing a hand holding a pen-like injector device with a visible cartridge inside. The device has a blue cap or portion on the left side and a grey tip on the right side. The illustration is labeled with a letter "B" in the upper left corner.*

FDA Label Image

Image 107

An instructional illustration showing a person’s hands removing a protective cap from the tip of an Ozempic injection pen. The image highlights the proper technique for cap removal, indicated by an arrow pointing away from the pen tip.*

FDA Label Image

Image 108

Instructional illustration showing a close-up of a hand twisting or removing the cap from a pen injector device, likely for Ozempic medication. The image depicts the proper way to hold and turn the pen cap before use.*

FDA Label Image

Image 109

Illustration showing the connection process of a pen needle to an injection device, with a hand holding the needle cap and an arrow indicating the direction to attach it.*

FDA Label Image

C (Image 11)

An instructional diagram showing a close-up of two hands; one hand is holding a small vial or device while the other hand is positioned to remove a cap or cover by pulling it away in the indicated direction (to the left). The image appears to demonstrate the first step in preparing or using the product, likely related to Ozempic injection preparation.*

FDA Label Image

Image 110

An instructional illustration showing a close-up of a hand holding an injection pen. The hand is depicted removing or attaching a cap to the pen needle, indicated by an arrow pointing outward from the needle tip.*

FDA Label Image

Image 111

Illustration showing how to check the flow symbol on the Ozempic injection pen. The image depicts hands holding the pen with an arrow indicating the flow check symbol is selected, signifying proper flow before injection.*

FDA Label Image

Image 112

Illustration showing a hand adjusting the dose selector on an Ozempic injection pen. The pen is partially visible with a blue body and a clear section for medication, demonstrating the proper way to set or change the dose before administration.*

FDA Label Image

Image 113

An instructional illustration showing how to adjust the dosage selector on an Ozempic pen injector. The image highlights rotating the dial to align with a dashed line to select a 2 mg dose. Visual cues include a close-up of the selector dial and the number 2 mg highlighted, indicating dose selection process for Ozempic injection.*

FDA Label Image

Image 114

An instructional diagram showing a close-up of a hand adjusting a blue dose counter on a pen or injector device. The dose counter window displays the number '2 mg', with an arrow indicating a turn or adjustment. Text beside the illustration reads 'Dose counter stopped: 2 mg left.'*

FDA Label Image

Image 115

An anatomical illustration showing the front and back view of a human torso with highlighted areas on the abdomen and outer thighs. This diagram typically indicates recommended injection sites for a medication.*

FDA Label Image

Image 116

An instructional illustration showing a hand holding an Ozempic pen injector with an arrow pointing downward toward the skin, indicating the injection site and direction for use of the device.*

FDA Label Image

Image 117

An instructional illustration showing a hand holding a pen injector device with a downward arrow indicating pressing action. A blue square with '0 mg' is displayed, suggesting dosage-related instructions for Ozempic pen use.*

FDA Label Image

Image 118

An instructional illustration showing a hand holding an Ozempic injection pen with a speech bubble that says "Count slowly: 1-2-3-4-5-6." The image guides the user to count six seconds, likely related to proper injection technique instructions from Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Image 119

An instructional illustration showing the tip of an Ozempic injection pen, with an upward facing arrow above it, likely indicating a step in the preparation or injection process. The diagram is simple and uses minimal colors, focusing on the pen and the arrow.*

FDA Label Image

D (Image 12)

An instructional illustration depicting a hand holding a prefilled pen injector, preparing to administer an injection. The image highlights the connection or attachment of a needle to the pen device, emphasizing proper handling technique.*

FDA Label Image

Image 120

Illustration showing a hand twisting the cap off a pen injector, likely demonstrating the first step in preparing the Ozempic pen for use.*

FDA Label Image

Image 121

An instructional illustration showing a vial top with grooves and a small liquid-dropping container above it, indicating to add drops into the vial's top grooves.*

FDA Label Image

Image 122

An instructional illustration showing hands peeling off a protective cap or cover from a device, with an arrow indicating the direction to remove the cap. The image suggests a step in the preparation or usage of the device.*

FDA Label Image

Image 123

An instructional illustration showing a close-up of a device with a separate cap. Two blue arrows indicate the direction to remove the cap from the device, pointing leftwards. The background is light blue with a small blue square containing a white 'S' in the top left corner.*

FDA Label Image

Image 124

Packaging label of Ozempic in a 2.68 mg/mL dosage form. The label shows the proprietary name Ozempic prominently with the strength of 2.68 mg/mL. The label also includes reference to the other strengths available in this set (.68 mg/mL and 1.34 mg/mL) and indicates Novo Nordisk Pharmaceutical Industries, LP as the labeler. The label is on a cylindrical container, likely a pen or injector device.*

FDA Label Image

Image 125

Ozempic 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL injectable solution pen packaging label shown. The label features the Novo Nordisk logo and branding with dosage strengths prominently displayed. It indicates the product is an injectable solution supplied in a pen device by Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Image 126

Ozempic injection carton label showing three available strengths: 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The label includes branding and dosage strength information. The labeler is Novo Nordisk Pharmaceutical Industries, LP. The packaging is primarily white with purple and orange design elements.*

FDA Label Image

Image 127

Packaging label for Ozempic injection, showing strengths 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The label includes the Novo Nordisk Pharmaceutical Industries, LP logo and branding. The label also displays the product name, strengths, and other regulatory information.*

FDA Label Image

Image 128

Ozempic 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL injectable solution labels shown on rectangular cartons. Each label features the brand name Ozempic prominently, the strengths indicated on the side, and the labeler Novo Nordisk Pharmaceutical Industries, LP. The packaging design has a clean, professional appearance with colored accents.*

FDA Label Image

Image 129

Ozempic injection vial label showing available strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The label includes the proprietary name Ozempic, the strength concentrations, and the labeler Novo Nordisk Pharmaceutical Industries, LP. The vial is designed for injectable use.*

FDA Label Image

E (Image 13)

An instructional illustration showing a person assembling or preparing a prefilled syringe, likely for injection. The hands are holding the syringe and a cap, demonstrating how to remove or attach the needle cover securely before use.*

FDA Label Image

Image 130

The image shows a carton label for Ozempic, a solution for injection available in three strengths: 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The label displays the Novo Nordisk Pharmaceutical Industries, LP logo and includes branding with various colors and the product name prominently.*

FDA Label Image

Image 131

Ozempic multidose pen injector packaging label displaying strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The label features the proprietary name Ozempic, the Novo Nordisk Pharmaceutical Industries, LP labeler name, and design elements including stylized lines and background in shades of purple and pink.*

FDA Label Image

Image 133

FDA Label Image

F (Image 14)

An instructional illustration showing a syringe with a needle being connected to a vial, with arrows indicating the direction of connection, related to medication preparation or administration.*

FDA Label Image

Warning 2 (Image 15)

Ozempic carton packaging for the injectable solution is shown with strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. The image depicts a box with the brand name Ozempic prominently displayed, along with the concentration and dosage form. The labeler name Novo Nordisk Pharmaceutical Industries, LP is visible.*

FDA Label Image

Dose 1 (Image 16)

Ozempic subcutaneous injection cartons in three strengths: 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. Each carton shows the Novo Nordisk pharmaceutical logo and labeler, Novo Nordisk Pharmaceutical Industries, LP. The packaging colors vary slightly between strengths but all are clearly branded as Ozempic.*

FDA Label Image

G (Image 17)

Instructional diagram showing a person performing a flow check on a pen-type injector. The illustration depicts pressing the button or plunger with the caption 'Flow check symbol selected' to ensure proper medication flow before injection.*

FDA Label Image

H (Image 18)

An instructional illustration depicting a hand holding a pen-like injector device with the cap being removed by pulling upward, indicated by a black arrow. This likely demonstrates preparation steps for using the injection device, associated with the Ozempic product from Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

Warning 3 (Image 19)

The packaging label for Ozempic, available in strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL, presented as a multi-dose pen injector. The label includes the Novo Nordisk logo and highlights the medication name prominently on the front. The label also shows patient instructions and dosage information for use with the pen injector.*

FDA Label Image

Dash 1 (Image 20)

The image shows three Ozempic prefilled pen cartridges at strengths of .68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. Each cartridge is labeled with the Ozempic brand name and strength. The labeler is Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

I (Image 21)

An instructional illustration showing a pen injector with a window display. The display shows a dotted line and '1 mg selected,' indicating how to select a dose of 1 mg on the pen.*

FDA Label Image

Warning 4 (Image 22)

The image shows the Ozempic pen injector packaging label by Novo Nordisk Pharmaceutical Industries, containing 2.68 mg/mL solution for subcutaneous injection. The label features black and magenta text on a white background, with instructions for use depicted on the device image, including numbered steps and dosage adjustment markings.*

FDA Label Image

J (Image 23)

An instructional illustration showing a hand turning the dose counter stopper on a pen injector, indicating that one dose is left. This image demonstrates how to adjust or check the dose counter on the device.*

FDA Label Image

K (Image 24)

An instructional diagram depicting the recommended injection sites for Ozempic .68 mg/mL, 1.34 mg/mL, or 2.68 mg/mL. The front and back of a human torso are shown, highlighting possible abdominal and thigh injection areas, as well as the upper arm, illustrating where the medication may be administered.*

FDA Label Image

L (Image 25)

An instructional illustration showing a hand holding a pen-like injection device with the other hand pulling down a blue cap or cover, indicated by a downward arrow. The image likely demonstrates the first step to prepare or use the injectable pen device.*

FDA Label Image

M (Image 26)

An instructional illustration showing a hand holding and preparing a pen injector device for use. The diagram includes a close-up view of the pen tip and an arrow indicating the direction to attach or remove a needle. The image is related to the Ozempic injection pen for subcutaneous administration.*

FDA Label Image

N (Image 27)

An instructional illustration showing a hand holding a syringe or pen device with a speech bubble instructing to 'Count slowly: 1-2-3-4-5-6,' indicating a step in an administration process or dosage timing.*

FDA Label Image

O (Image 28)

An instructional illustration showing a pen injector device with an arrow pointing upward, indicating the step of removing or lifting the cap from the pen. No text is visible. The image visually guides users on how to begin preparing the pen for use, associated with the Ozempic medication by Novo Nordisk.*

FDA Label Image

Warning 5 (Image 29)

The image shows the carton for Ozempic injection in 2.68 mg/mL strength. The packaging includes the brand name Ozempic, the concentration 2.68 mg/mL, and dosing information for injection use. It is manufactured by Novo Nordisk Pharmaceutical Industries, LP. The label features color-coded design elements and clearly states dosage in a pre-filled pen format.*

FDA Label Image

P (Image 30)

An instructional diagram showing a hand holding an Ozempic injection pen with the cap being removed by pulling it upwards. A blue arrow indicates the direction to pull the cap off the pen before use.*

FDA Label Image

Q (Image 31)

An instructional diagram illustrating the process of preparing or opening a medication vial. The image shows a vial with its protective top and an arrow indicating the removal or attachment action with a cap or tool above the vial.*

FDA Label Image

R (Image 32)

An instructional illustration showing a close-up of hands preparing an injection pen. It depicts one hand holding the pen while the other hand is peeling off a protective cap or seal from the needle area, demonstrating a step in the injection preparation process.*

FDA Label Image

S (Image 33)

An instructional diagram showing two arrows pointing towards an injection pen device cap, illustrating the action of attaching or removing the cap. This image relates to the use or handling of the injection device, likely for Ozempic.*

FDA Label Image

Warning 6 (Image 34)

Ozempic cartridge pen labels showing strengths 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. Each label displays the proprietary name Ozempic, the strength in mg/mL, and the labeler Novo Nordisk Pharmaceutical Industries, LP. The labels are white with purple accents and include distinguishable numeric strength indicators.*

FDA Label Image

Warning 7 (Image 35)

Ozempic multi-dose pen labels showing strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. Each label states the proprietary name Ozempic and the concentrations clearly. The labels are primarily orange and white and include the Novo Nordisk Pharmaceutical Industries, LP name as the labeler.*

FDA Label Image

Qr1 (Image 36)

FDA Label Image

Bull 1 (Image 37)

FDA Label Image

Warning 8 (Image 38)

Packaging label for Ozempic, featuring three separate panels for the strengths 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL. Each panel shows the proprietary name Ozempic, the concentration in mg/mL, and the labeler Novo Nordisk Pharmaceutical Industries, LP. The label layout includes dosage form and packaging details and a barcode on the right side.*

FDA Label Image

Device 2 (Image 39)

An instructional diagram showing the components and features of the Ozempic pen and NovoFine Plus needle. It labels parts including the pen cap, pen window, dose counter, dose pointer, dose selector, and dose button on the pen, as well as the outer needle cap, inner needle cap, needle, and paper tab of the needle. The diagram also highlights the flow check symbol and dashed line used for dose guidance.*

FDA Label Image

A (Image 40)

An instructional illustration showing hands manipulating a pen-style injector, likely for the medication Ozempic. The image appears to demonstrate how to remove or adjust a part of the injector device, possibly the needle or cap, as part of medication preparation or administration.*

FDA Label Image

B (Image 41)

An instructional illustration showing a hand holding an injectable pen device with the cap being removed or attached. This image likely depicts a step in the use or preparation of the Ozempic injectable pen by Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

C (Image 42)

An instructional diagram showing a hand holding and preparing a medical injection pen, with an arrow indicating a step of pulling or pushing on the pen's end. The image is a step in using the Ozempic pen injection device.*

FDA Label Image

D (Image 43)

Illustration showing a hand holding the Ozempic pen injector near the needle area, demonstrating the action of attaching or securing the needle to the pen device. The image highlights proper handling technique for assembling the injector pen before use.*

FDA Label Image

E (Image 44)

An instructional illustration showing a hand attaching a needle or pen tip to an injection device, with a protective cover being removed. This image is likely part of the usage directions for Ozempic injection pens by Novo Nordisk Pharmaceutical Industries, LP.*

FDA Label Image

F (Image 45)

An instructional illustration showing the preparation of a medication injection. The image depicts an injection pen with a protective cap being removed by a hand, indicating a step in medication administration for products like Ozempic.*

FDA Label Image

Warning 9 (Image 46)

Packaging label for Ozempic injectable solution in a 2 mL single-dose prefilled pen, containing 1.34 mg/mL of the active ingredient. The label shows Novo Nordisk Pharmaceutical Industries, LP as the labeler and includes storage and usage instructions. The pen is orange colored with a clear dosing display window.*

FDA Label Image

Dose 2 (Image 47)

Ozempic injectable solution in a 0.68 mg/mL strength is displayed on the packaging label. The label highlights the brand name Ozempic, the concentration of 0.68 mg/mL, and the labeler Novo Nordisk Pharmaceutical Industries, LP. The packaging is primarily orange with white and gray sections, and includes a depiction of the drug vial and pen injector.*

FDA Label Image

G (Image 48)

Instructional illustration showing a finger pressing a flow check feature on a device, with a displayed flow check symbol indicating selection. This diagram assists with proper operation of a medication delivery device related to Ozempic provided by Novo Nordisk.*

FDA Label Image

H (Image 49)

Illustration showing a hand holding a pen-like injector device, presumably a medication injector. The illustration indicates to remove the blue cap by pulling it upwards, as shown by a large arrow. A small cap is shown detached and held above the main device.*

FDA Label Image

Warning 10 (Image 50)

Packaging label for Ozempic in a 0.68 mg/mL dosage form. The label prominently displays the proprietary name Ozempic along with its strength and manufacturer, Novo Nordisk Pharmaceutical Industries, LP. This is a solution for injection, clearly marked on the label, suitable for patient use.*

FDA Label Image

Dash 2 (Image 51)

Ozempic 2.68 mg/mL solution in a prefilled pen cartridge label from Novo Nordisk Pharmaceutical Industries, LP. The clear plastic cartridge shows dosing marks and contains a visible orange-yellow solution. The cartridge is part of a pen injection device designed for subcutaneous use.*

FDA Label Image

I (Image 52)

An instructional diagram illustrating how to set the dosage on a pen injector device. It shows a close-up of the dose selector with a dotted line example selecting 0.25 mg and an arrow pointing to the dial mechanism, indicating the user can turn the dial to select the desired dose, such as 0.5 mg.*

FDA Label Image

Warning 11 (Image 53)

The image shows the label of Ozempic, a 2.68 mg/mL injectable solution. The product name Ozempic, concentration 2.68 mg/mL, and dosage form as an injectable solution are visible. The label includes Novo Nordisk Pharmaceutical Industries, LP as the labeler. Additional graphical elements and barcodes are present on the label.*

FDA Label Image

J (Image 54)

An instructional diagram showing hands holding and using a dose counter pen device labeled 'Ozempic'. The display on the pen shows a numeric dose setting, with an example dose of 0.25 mg highlighted, demonstrating dose selection or adjustment for Ozempic injectable solution.*

FDA Label Image

K (Image 55)

An instructional illustration showing front and back views of a human torso with four designated injection sites marked on the abdomen and thighs, typically used for subcutaneous injection guidance.*

FDA Label Image

L (Image 56)

An instructional illustration showing a hand holding a pen-like injection device vertically against the abdomen. A downward arrow indicates the direction to press the device against the skin for injection.*

FDA Label Image

M (Image 57)

An instructional diagram showing a hand holding a pen-like injection device with a needle exposed, illustrating the proper technique for administering an injection. This image is associated with Ozempic, a medication by Novo Nordisk Pharmaceutical Industries, LP, available in strengths 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL.*

FDA Label Image

N (Image 58)

An instructional illustration showing a hand holding a pen-like injector device with the text bubble 'Count slowly: 1-2-3-4-5-6,' suggesting a step for slow counting during use.*

FDA Label Image

O (Image 59)

An instructional diagram showing a pen injector with an arrow pointing upward, indicating the action to remove the cap from the device before use.*

FDA Label Image

Warning 12 (Image 60)

Ozempic injection carton and vial labels showing strengths of 0.68 mg/mL, 1.34 mg/mL, and 2.68 mg/mL of the active ingredient in a prefilled pen device. The labeler is Novo Nordisk Pharmaceutical Industries, LP. The packaging displays the product name and strength prominently in blue and pink text on a white background.*

FDA Label Image

P (Image 61)

An instructional illustration showing a hand twisting off the blue cap of a pen injector device, demonstrating how to prepare the device for use.*

FDA Label Image

Q (Image 62)

An instructional illustration showing the step of inserting a pen needle onto a medication pen. The image features a hand holding a small pen needle above a pen device, with an arrow indicating the needle should be pushed downward onto the pen.*

FDA Label Image

R (Image 63)

Illustration showing hands preparing an injection pen, specifically demonstrating removal of the protective cap from the needle. The image is instructional, related to the administration of Ozempic injection pen by Novo Nordisk.*

FDA Label Image

S (Image 64)

An instructional diagram showing the disassembly of a pen device, possibly for Ozempic injection. The image depicts the removal of the pen cap by pulling it away from the pen body, indicated by directional arrows.*

FDA Label Image

Warning 13 (Image 65)

Packaging label for Ozempic 1.34 mg/mL, a solution for injection in a 3 mL pre-filled pen. The label shows Novo Nordisk Pharmaceutical Industries, LP as the manufacturer and includes detailed usage instructions and product information on the pen.*

FDA Label Image

Warning 14 (Image 66)

Ozempic 2.68 mg/mL injection cartridge carton from Novo Nordisk Pharmaceutical Industries, LP. The label shows the proprietary name Ozempic and strength 2.68 mg/mL, indicating it is a pre-filled pen or cartridge dosage form. Packaging includes branding and regulatory information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.